3 Dividend Stocks Worth Buying Now?
Thanks to surging stock prices over the past two years, dividend yields on major stock indices have fallen to fairly low levels. The S&P 500, for instance, currently carries an average yield of just 1.3%.
The mature companies in the Dow Jones Industrial Average fare a bit better, and some of them offer yields that exceed the S&P 500 several times over. » Read more about: 3 Dividend Stocks Worth Buying Now? »
Read More
World War III: 2 Must-Own Defense Stocks
If you’re not paying attention to the conflict in Ukraine, the takeaway is it is escalating rapidly. Among the latest developments is Germany’s approval of Poland’s request to send Leopard tanks through its country to Ukraine.
Another striking development has been the call by Boris Johnson and others to permit Ukraine’s entry into NATO,
» Read more about: World War III: 2 Must-Own Defense Stocks »
Read MoreCheapest Stock in Buffett’s Portfolio: 51% Upside?
If you’re following Warren Buffett’s investment strategies, you may have come across Ally Financial, one of Berkshire Hathaway’s more recent holdings. Despite a challenging 2022, this financial services company boasts several attractive features. In fact, by our calculations, it’s currently the cheapest stock in Buffett’s Berkshire Hathaway portfolio.
Ally Financial is an industry leader in online banking and auto lending,
» Read more about: Cheapest Stock in Buffett’s Portfolio: 51% Upside? »
Read More“1 Extraordinary Stock with 12x Upside” Analyst Claims
One analyst with an astonishing track record claims Roku could rise by as much as 12x from current levels, so we decided to investigate whether there is any merit to bullish forecast.
Who is the analyst and is she worth listening to? That’s up for debate. At her heights, Cathie Wood was revered as the prognosticator extraordinaire,
» Read more about: “1 Extraordinary Stock with 12x Upside” Analyst Claims »
Read More
Massive Upside In Big Money Pharma Favorite?
Iovance Biotherapeutics (NASDAQ:IOVA) is a fledgling pharmaceutical company that specializes in the use of immune therapies for cancer treatment. Specifically, Iovance is exploring new applications of tumor infiltrating lymphocyte (TIL) therapy, utilizing cells that the human body naturally produces to attack cancerous tumors.
There was lots of hype about this next-generation cancer treatment company but its share price has been decidedly lackluster this year,
» Read more about: Massive Upside In Big Money Pharma Favorite? »
Read MoreThe Ivy
Why This Stock Could Be a Dividend Powerhouse for the Next Decade
Brookfield Renewable (NYSE: BEPC, BEP) doesn’t just participate in the energy transition but profits from it in ways few investors fully appreciate.
While many renewable stocks have stumbled in the face of rising rates and public market disinterest, Brookfield’s long-term game plan is quietly delivering results. One of the clearest signs? The dividend streak is 10 years.
» Read more about: Why This Stock Could Be a Dividend Powerhouse for the Next Decade »
Read MoreThe Spotlight
1 Stock That Will Pay You Monthly
When Charlie Munger was a boy, he described an encounter he had with an older man who seemed to work very little but had a lot of money. Curious what the man did he questioned the line of business he was in and discovered to his surprise he “rendered dead horses.” What Charlie learned from the conversation was less about horses and more about how one man got rich because he was the only player in that market.
» Read more about: 1 Stock That Will Pay You Monthly »
Read MoreThe Daily
The Stock Market Has a Serious Federal Reserve Problem — and It's Not What You Think It Is
A historic level of division at America’s foremost financial institution can undermine the stability of Wall Street.
The third year of Wall Street’s bull market rally proved what a wealth-creating machine the stock market can be. When the closing bell rang on Dec. 31, the iconic Dow Jones Industrial Average (^DJI 0.17%),